Benitec Biopharma Inc (BNTC)
$9.02
+0.14
(+1.63%)▲
Performance
- $8.65$9.02$9.02
4.1%
Downside
Day's Volatility :4.1%
Upside
0.0%
- $2.69$10.88$9.02
70.18%
Downside
52 Weeks Volatility :75.28%
Upside
17.1%
Returns
| Period | Benitec Biopharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 21.56% | 0.0% |
6 Months | 82.96% | 0.0% |
1 Year | 196.71% | 0.0% |
3 Years | -86.43% | -22.3% |
Highlights
Market Capitalization | 91.0M |
Book Value | $4.22 |
Earnings Per Share (EPS) | -9.6 |
PEG Ratio | 0.0 |
Wall Street Target Price | 19.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -307028.56% |
Return On Assets TTM | -115.7% |
Return On Equity TTM | -267.59% |
Revenue TTM | 7.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 12.5% |
Gross Profit TTM | 75.0K |
EBITDA | -21.4M |
Diluted Eps TTM | -9.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.22 |
EPS Estimate Next Year | -1.86 |
EPS Estimate Current Quarter | -0.78 |
EPS Estimate Next Quarter | -0.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 118.07%
Technicals Summary
Sell
Neutral
Buy
Benitec Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Benitec Biopharma Inc | 2.5% | 82.96% | 196.71% | -86.43% | -94.21% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Benitec Biopharma Inc | NA | NA | 0.0 | -5.22 | -2.68 | -1.16 | NA | 4.22 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Benitec Biopharma Inc | Buy | $91.0M | -94.21% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Benitec Biopharma Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 54.0K → 6.0K (in $), with an average decrease of 50.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -6.79M → -4.27M (in $), with an average increase of 58.9% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 155.6%
Institutional Holdings
Suvretta Capital Management, LLC
16.77%HHG PLC
8.93%Adage Capital Partners Gp LLC
8.34%Franklin Resources Inc
7.90%Vanguard Group Inc
2.13%Simplify Asset Management Inc.
0.51%
Company Information
benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
Organization | Benitec Biopharma Inc |
Employees | 16 |
CEO | Dr. Jerel A. Banks M.D., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$9.02
+1.63%
Keyarch Acquisition Corp
$9.02
+1.63%
Connexa Sports Technologies Inc
$9.02
+1.63%
Us Value Etf
$9.02
+1.63%
First Wave Biopharma Inc
$9.02
+1.63%
Global X Msci Next Emerging
$9.02
+1.63%
Fat Projects Acquisition Corp
$9.02
+1.63%
Capital Link Global Fintech
$9.02
+1.63%
Applied Uv Inc
$9.02
+1.63%